Novo Nordisk (NVO) Fundamental Analysis: Revenue, Earnings & Valuation

6.51 / 10

Outperform

Novo Nordisk's fundamentals are solid, rated Outperform with a 6.5/10 score. Key positives include a healthy operating revenue YoY growth of 6.43% and strong interest-coverage at 44.38%, both ranking in favorable quartiles. However, the PB-ROE factor is negative, and several ratios (Days Sales Outstanding, Cost of Sales, Income Tax/Profit) fall in less-ideal groups, tempering the outlook. Overall, the company's asset quality and profitability remain constructive despite some red flags.

Analysis Checks(9/10)

Revenue-MV

Value-0.26

Score3/3

Weight23.06%

1M Return11.66%

Days sales outstanding

Value83.17

Score3/3

Weight2.00%

1M Return1.30%

Profit-MV

Value3.42

Score3/3

Weight23.10%

1M Return12.21%

PB-ROE

Value-0.63

Score0/3

Weight3.96%

1M Return2.29%

Income tax / Total profit (%)

Value21.53

Score2/3

Weight3.77%

1M Return2.06%

Interest coverage ratio (EBIT / Interest expense) (%)

Value44.38

Score2/3

Weight-0.96%

1M Return-0.66%

Operating revenue (YoY growth rate %)

Value6.43

Score2/3

Weight0.83%

1M Return0.55%

Cost of sales ratio (%)

Value19.02

Score3/3

Weight1.17%

1M Return0.72%

Asset-MV

Value-0.53

Score3/3

Weight26.34%

1M Return12.82%

Cash-MV

Value-1.05

Score2/3

Weight16.73%

1M Return7.70%

Is NVO undervalued or overvalued?

NVO scores 6.51/10 on fundamentals and holds a Discounted valuation at present. Backed by its 60.70% ROE, 33.14% net margin, 13.14 P/E ratio, 6.94 P/B ratio, and 15.16% earnings growth, these metrics solidify its Outperform investment rating.